{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:51:14Z","timestamp":1771487474801,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s10792-008-9218-2","type":"journal-article","created":{"date-parts":[[2008,4,9]],"date-time":"2008-04-09T11:03:01Z","timestamp":1207738981000},"page":"311-316","source":"Crossref","is-referenced-by-count":25,"title":["Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis"],"prefix":"10.1007","volume":"28","author":[{"given":"Salim","family":"Ben Yahia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl P.","family":"Herbort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Jenzeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Hmidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riadh","family":"Messaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moncef","family":"Khairallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,10]]},"reference":[{"key":"9218_CR1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0002-9394(02)01947-5","volume":"135","author":"A Adan","year":"2003","unstructured":"Adan A, Mateo C, Wolley-Dod C (2003) Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol 135:386\u2013387","journal-title":"Am J Ophthalmol"},{"key":"9218_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archopht.124.5.741","volume":"124","author":"R Wirthlin","year":"2006","unstructured":"Wirthlin R, Song A, Song J, Rosenfeld PJ (2006) Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis. Arch Ophthalmol 124:741\u2013743","journal-title":"Arch Ophthalmol"},{"key":"9218_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/09273940490518883","volume":"13","author":"Y Perentes","year":"2005","unstructured":"Perentes Y, Van Tran T, Sickenberg M, Herbort CP (2005) Subretinal neovascular membranes complicating uveitis: frequency, treatments and visual outcome. Ocul Immunol Inflamm 13:219\u2013224","journal-title":"Ocul Immunol Inflamm"},{"key":"9218_CR4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD et\u00a0al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372","journal-title":"Ophthalmology"},{"key":"9218_CR5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/01.iae.0000240121.28034.c3","volume":"26","author":"K Laud","year":"2006","unstructured":"Laud K, Spaide RF, Freund KB et\u00a0al (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960\u2013963","journal-title":"Retina"},{"key":"9218_CR6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1600-0420.2006.00762.x","volume":"84","author":"A Teixeira","year":"2006","unstructured":"Teixeira A, Moraes N, Farah ME, Bonomo PP (2006) Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 84:835\u2013836","journal-title":"Acta Ophthalmol Scand"},{"key":"9218_CR7","first-page":"3158","volume":"41","author":"N Kwak","year":"2000","unstructured":"Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158\u20133164","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9218_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2002-30662","volume":"219","author":"Y Perentes","year":"2002","unstructured":"Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelial growth factor (VEGF) expression in Eales\u2019 disease. Klin Monatsbl Augenheilk 219:11\u201314","journal-title":"Klin Monatsbl Augenheilk"},{"key":"9218_CR9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G et\u00a0al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"9218_CR10","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/IAE.0b013e31815e9834","volume":"27","author":"A Adan","year":"2007","unstructured":"Adan A, Mateo C, Navarro R et\u00a0al (2007) Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27:1180\u20131186","journal-title":"Retina"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-008-9218-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-008-9218-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-008-9218-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T20:30:17Z","timestamp":1559248217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-008-9218-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["9218"],"URL":"https:\/\/doi.org\/10.1007\/s10792-008-9218-2","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,10]]}}}